US diet drug concept stocks generally closed down on Thursday, Viking Therapeutics closed down 11.47%, Bojian fell more than 2.2%, Lilly fell more than 2%, Novo Nordisk's ADR fell 1.2%, and Amgen and Schudi Biotech's ADR also fell by at least 0.5%. Roche

US diet drug concept stocks generally closed down on Thursday, Viking Therapeutics closed down 11.47%, Bojian fell more than 2.2%, Lilly fell more than 2%, Novo Nordisk's ADR fell 1.2%, and Amgen and Schudi Biotech's ADR also fell by at least 0.5%. Roche Holdings' ADR closed up 3.98% for the third consecutive trading day, hitting a new high since March 14.

Zhitong Finance13minutes ago

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.23% on an annualized basis producing an average annual return of 20.06%. Currently, Novo Nordisk has a market capitaliza

Benzinga15:30

Viking Falls After Roche's Obesity Drug Data

Seeking Alpha12:37

Diet pills are carrying the Danish economy, and after only a few months, the official GDP growth rate guidelines have doubled

① Based on factors such as Novo Nordisk's rapid expansion, the Danish Ministry of Economy doubled this year's GDP growth rate in the latest forecast; ② The Danish economy grew by 1.8% last year, but it will fall into recession after removing the growth rate of the pharmaceutical industry.

cls.cnMay 16 10:00

Diet drug concept stocks declined, Roche announced positive results for GLP-1/GIP Phase 1 of the new drug

Glonghui, May 16 | Viking Therapeutics fell 3.22%, Lilly fell 1.4%, Amgen fell 1.34%, and Novo Nordisk fell 1.25%. According to the news, Swiss competitor Roche announced that its phase 1 trial of its GLP-1/GIP dual receptor agonist CT-388 in obese people had positive results. Compared with placebo, healthy and obese adults can lose weight significantly by injecting CT-388 subcutaneously once a week for 24 weeks. The average weight loss rate after placebo adjustment was 18.8% (p value < 0.001), which achieved statistical compatibility

Gelonghui FinanceMay 16 09:51

3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

Yahoo FinanceMay 16 09:13